{"filing":{"accession_number":"0001193125-26-308899","cik":"0001800315","ticker":"DMRA","company_name":"Damora Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"dmra-20260716.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/dmra-20260716.htm"},"events":[{"id":18754,"run_id":16870,"accession_number":"0001193125-26-308899","anchor_item_number":"3.03","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Damora Therapeutics completed a redomestication from Delaware to the Cayman Islands, effective July 16, 2026, following stockholder approval at a Special Meeting on February 9, 2026. The redomestication involved automatic conversion of all share classes, issuance of a new CUSIP, and amendments to the company's articles of association and bylaws, materially modifying shareholder rights and the company's legal jurisdiction and governance framework.","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17657,"accession_number":"0001193125-26-308899","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 1.01 disclosure centers on entry into indemnification agreements with directors and officers, which is a governance matter. While Item 1.01 typically covers material definitive agreements of operational or financial significance, the substance here is governance-related (director/officer indemnification). The supplemental press release reveals the broader context: a redomestication from Delaware to Cayman Islands, which is a material corporate governance restructuring affecting the company's domicile and legal structure, though the indemnification agreements themselves are routine governance documentation. This is material to investors as it reflects a significant change in corporate jurisdiction and governance framework.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17658,"accession_number":"0001193125-26-308899","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a redomestication of Damora Therapeutics from Delaware to the Cayman Islands, effective July 16, 2026, following stockholder approval at a Special Meeting on February 9, 2026. This is a material governance event involving a change in the company's jurisdiction of incorporation and governing law, with automatic conversion of all share classes and modification of shareholder rights. While the company states the redomestication did not change business, management, or material contracts, the shift from Delaware to Cayman Islands law and the resulting changes to the company's articles of association and shareholder rights constitute a significant governance restructuring that would affect investor assessment of the registrant's corporate structure and regulatory environment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17659,"accession_number":"0001193125-26-308899","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of a redomestication from Delaware to the Cayman Islands, effective July 16, 2026, which is a material change to the company's corporate domicile and governance structure. While Item 5.03 covers amendments to articles of incorporation or bylaws and changes in fiscal year, this redomestication—involving automatic conversion of all shares and a new CUSIP—is a significant governance event that affects the registrant's legal jurisdiction and organizational form. The company explicitly states the redomestication was previously approved by the board and stockholders at a Special Meeting on February 9, 2026, confirming its governance materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17660,"accession_number":"0001193125-26-308899","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces completion of a redomestication from Delaware to Cayman Islands, effective July 16, 2026, with stockholder approval obtained at a Special Meeting on February 9, 2026. This is a material governance and corporate structure event that affects the registrant's domicile and legal jurisdiction, though it does not change business operations, management, or assets. The event is governance-related but does not fit the specific categories of exec_departure, exec_appointment, exec_compensation, auditor_change, or shareholder_vote_results (the vote already occurred and is not the subject of this disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17657,"accession_number":"0001193125-26-308899","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 1.01 disclosure centers on entry into indemnification agreements with directors and officers, which is a governance matter. While Item 1.01 typically covers material definitive agreements of operational or financial significance, the substance here is governance-related (director/officer indemnification). The supplemental press release reveals the broader context: a redomestication from Delaware to Cayman Islands, which is a material corporate governance restructuring affecting the company's domicile and legal structure, though the indemnification agreements themselves are routine governance documentation. This is material to investors as it reflects a significant change in corporate jurisdiction and governance framework.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-07-20"},{"id":17658,"accession_number":"0001193125-26-308899","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a redomestication of Damora Therapeutics from Delaware to the Cayman Islands, effective July 16, 2026, following stockholder approval at a Special Meeting on February 9, 2026. This is a material governance event involving a change in the company's jurisdiction of incorporation and governing law, with automatic conversion of all share classes and modification of shareholder rights. While the company states the redomestication did not change business, management, or material contracts, the shift from Delaware to Cayman Islands law and the resulting changes to the company's articles of association and shareholder rights constitute a significant governance restructuring that would affect investor assessment of the registrant's corporate structure and regulatory environment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-07-20"},{"id":17659,"accession_number":"0001193125-26-308899","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses completion of a redomestication from Delaware to the Cayman Islands, effective July 16, 2026, which is a material change to the company's corporate domicile and governance structure. While Item 5.03 covers amendments to articles of incorporation or bylaws and changes in fiscal year, this redomestication—involving automatic conversion of all shares and a new CUSIP—is a significant governance event that affects the registrant's legal jurisdiction and organizational form. The company explicitly states the redomestication was previously approved by the board and stockholders at a Special Meeting on February 9, 2026, confirming its governance materiality.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-07-20"},{"id":17660,"accession_number":"0001193125-26-308899","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces completion of a redomestication from Delaware to Cayman Islands, effective July 16, 2026, with stockholder approval obtained at a Special Meeting on February 9, 2026. This is a material governance and corporate structure event that affects the registrant's domicile and legal jurisdiction, though it does not change business operations, management, or assets. The event is governance-related but does not fit the specific categories of exec_departure, exec_appointment, exec_compensation, auditor_change, or shareholder_vote_results (the vote already occurred and is not the subject of this disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:01:51.854498+00:00","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-07-20"}]}